Olokizumab is under clinical development by R-Pharm and currently in Phase III for Sarcoidosis. According to GlobalData, Phase III drugs for Sarcoidosis does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Olokizumab LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Olokizumab overview

Olokizumab (Artlegia) is a humanized monoclonal antibody. It is formulated as solution for subcutaneous route of administration. Artlegia is indicated for treatment of rheumatoid arthritis and cytokine storm, which is the leading cause of death in coronavirus infection COVID-19.
Olokizumab (CDP- 6038) is under development for the treatment of  active juvenile idiopathic arthritis, acute respiratory distress syndrome and fibrosing interstitial lung disease, idiopathic interstitial pneumonia (IIP); interstitial lung fibrosis; sarcoidosis. The drug candidate is administered subcutaneously. The drug candidate is a humanized antibody of the IgG4 isotype that acts by targeting interleukin-6 (IL-6). Olokizumab was also under development for the treatment of Crohn's disease, moderate-to-severe rheumatoid arthritis and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

R-Pharm overview

R-Pharm (R Pharm) is a pharmaceutical company. It carries out the production of drugs, active pharmaceutical ingredients, laboratory equipment and high-tech medical systems. The company’s pipeline products include RPH-001, RPH-002, RPH-120, RPH-075, RS-113 and RS-110 for oncology; Nemonoxacin, Narlaprevir, Cefilavancin and Delamanid which targets antimicrobial; Olokizumab, Goflikicept, RPH-035 and Etanercept for anti-infammatory and products. Its therapeutic areas are oncology, nephrology, cardiology, virology and hepatitis, drug treatment, intensive therapy and others. The company collaborates with pharmaceutical and biotechnology companies. It has operations in Russia, the US, Azerbaijan, Uzbekistan, Kyrgyzstan, Kazakhstan, Belarus and Germany. R-Pharm is headquartered in Moscow, Russia.

For a complete picture of Olokizumab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 12 April 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.